Full-length telomerase reverse transcriptase messenger RNA is an independent prognostic factor in neuroblastoma

American Journal of Pathology

Volumn 162, Issue 3, 2003, Pages 1019-1026

  Krams, Matthias ^a   Hero, Barbara ^b   Berthold, Frank ^b   Parwaresch, Reza ^a   Harms, Dieter ^a   Rudolph, Pierre ^a  

^a UNIVERSITY OF KIEL   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

TELOMERASE;

ALTERNATIVE RNA SPLICING; ARTICLE; CANCER CLASSIFICATION; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME MECHANISM; ENZYME REGULATION; FEMALE; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NEUROBLASTOMA; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0344211837     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)63896-5     Document Type: Article

References (34)

1. Maris JM, Matthay KK: Molecular biology of neuroblastoma. J Clin Oncol 1999, 17:2264-2279
2. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM: Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984, 224:1121-1124
3. Christiansen H, Lampert F: Tumour karyotype discriminates between good and bad prognostic outcome in neuroblastoma. Br J Cancer 1988, 57:121-126
4. Bown N, Cotterill S, Lastowska M, O'Neill S, Pearson AD, Plantaz D, Meddeb M, Danglot G, Brinkschmidt C, Christiansen H, Laureys G, Speleman F: Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med 1999, 340:1954-1961
5. Brodeur GM, Maris JM, Yamashiro DJ, Hogarty MD, White PS: Biology and genetics of human neuroblastomas. J Pediatr Hematol Oncol 1997, 19:93-101
6. Hiyama E, Hiyama K, Yokoyama T, Matsuura Y, Piatyszek MA, Shay JW: Correlating telomerase activity levels with human neuroblastoma outcomes. Nat Med 1995, 1:249-255
7. Poremba C, Scheel C, Hero B, Christiansen H, Schaefer KL, Nakayama JI, Berthold F, Juergens H, Boecker W, Dockhorn-Dworniczak B: Telomerase activity and telomerase subunits gene expression patterns in neuroblastoma: a molecular and immunohistochemical study establishing prognostic tools for fresh-frozen and paraffin-embedded tissues. J Clin Oncol 2000, 18:2582-2592
8. Rudolph P, Schubert C, Tamm S, Heidorn K, Hauschild A, Michalska I, Majewski S, Krupp G, Jablonska S, Parwaresch R: Telomerase activity in melanocytic lesions: a potential marker of tumor biology. Am J Pathol 2000, 156:1425-1432
9. Bonatz G, Frahm SO, Klapper W, Helfenstein A, Heidorn K, Jonat W, Krupp G, Parwaresch R, Rudolph P: High telomerase activity is associated with cell cycle deregulation and rapid progression in endometrioid adenocarcinoma of the uterus. Hum Pathol 2001, 32:605-614
10. Streutker CJ, Thorner P, Fabricius N, Weitzman S, Zielenska M: Telomerase activity as a prognostic factor in neuroblastomas. Pediatr Dev Pathol 2001, 4:62-67
11. Harley CB, Futcher AB, Greider CW: Telomeres shorten during ageing of human fibroblasts. Nature 1990, 345:458-460
12. Wright WE, Brasiskyte D, Piatyszek MA, Shay JW: Experimental elongation of telomeres extends the lifespan of immortal x normal cell hybrids. EMBO J 1996, 15:1734-1741
13. Shay JW, Bacchetti S: A survey of telomerase activity in human cancer. Eur J Cancer 1997, 33:787-791
14. Kelland LR: Telomerase inhibitors: targeting the vulnerable end of cancer? Anticancer Drugs 2000, 11:503-513
15. Mergny JL, Lacroix L, Teulade-Fichou MP, Hounsou C, Guittat L, Hoarau M, Arimondo PB, Vigneron JP, Lehn JM, Riou JF, Garestier T, Helene C: Telomerase inhibitors based on quadruplex ligands selected by a fluorescence assay. Proc Natl Acad Sci USA 2001, 98:3062-3067
16. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, Shay JW: Specific association of human telomerase activity with immortal cells and cancer. Science 1994, 266:2011-2015
17. Hisatomi H, Nagao K, Kanamaru T, Hiyama E: Levels of telomerase catalytic subunit mRNA as a predictor of potential malignancy. Int J Oncol 1999, 14:727-732
18. Schneider-Stock R, Jaeger V, Rys J, Epplen JT, Roessner A: High telomerase activity and high HTRT mRNA expression differentiate pure myxoid and myxoid/round-cell liposarcomas. Int J Cancer 2000, 89:63-68
19. Gunther T, Schneider-Stock R, Hackel C, Pross M, Schulz HU, Lippert H, Roessner A: Telomerase activity and expression of hTRT and hTR in gastrointestinal stromal tumors in comparison with extragastrointestinal sarcomas. Clin Cancer Res 2000, 6:1811-1818
20. Feng J, Funk WD, Wang SS, Weinrich SL, Avilion AA, Chiu CP, Adams RR, Chang E, Allsopp RC, Yu J: The RNA component of human telomerase. Science 1995, 269:1236-1241
21. Kilian A, Bowtell DD, Abud HE, Hime GR, Venter DJ, Keese PK, Duncan EL, Reddel RR, Jefferson RA: Isolation of a candidate human telomerase catalytic subunit gene, which reveals complex splicing patterns in different cell types. Hum Mol Genet 1997, 6:2011-2019
22. Meyerson M, Counter CM, Eaton EN, Ellisen LW, Steiner P, Caddle SD, Ziaugra L, Beijersbergen RL, Davidoff MJ, Liu Q, Bacchetti S, Haber DA: hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 1997, 90:785-795
23. Nakamura TM, Morin GB, Chapman KB, Weinrich SL, Andrews WH, Lingner J, Harley CB, Cech TR: Telomerase catalytic subunit homologs from fission yeast and human. Science 1997, 277:955-959
24. Harrington L, McPhail T, Mar V, Zhou W, Oulton R, Bass MB, Arruda I, Robinson MO: A mammalian telomerase-associated protein. Science 1997, 275:973-977
25. Ramakrishnan S, Eppenberger U, Mueller H, Shinkai Y, Narayanan R: Expression profile of the putative catalytic subunit of the telomerase gene. Cancer Res 1998, 58:622-625
26. Avilion AA, Platyszek MA, Gupta J, Shay JW, Bacchetti S, Greider CW: Human telomerase RNA and telomerase activity in immortal cell lines and tumor tissues. Cancer Res 1996, 56:645-650
27. Krams M, Claviez A, Heidorn K, Krupp G, Parwaresch R, Harms D, Rudolph P: Regulation of telomerase activity by alternate splicing of human telomerase reverse transcriptase mRNA in a subset of neuroblastomas. Am J Pathol 2001, 159:1925-1932
28. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, De Bernardi B, Evans AE, Favrot M, Hedborg F: Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. Prog Clin Biol Res 1994, 385:363-369
29. Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B, Stram DO, Gerbing RB, Lukens JN, Matthay KK, Castleberry RP: The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 1999, 86:364-372
30. Berthold F: Neuroblastom. Kompendium Internistische Onkologie, ed 2. Edited by Schmoll, Höffken, Possinger. Heidelberg, Springer, 1997, pp 1805-1819
31. Hiyama E, Hiyama K, Yokoyama T, Ichikawa T, Matsuura Y: Length of telomeric repeats in neuroblastoma: correlation with prognosis and other biological characteristics. Jpn J Cancer Res 1992, 83:159-164
32. Hiyama E, Hiyama K, Yokoyama T, Fukuba I, Yamaoka H, Shay JW, Matsuura Y: Rapid detection of MYCN gene amplification and telomerase expression in neuroblastoma. Clin Cancer Res 1999, 5:601-609
33. Ulaner GA, Hu JF, Vu TH, Giudice LC, Hoffman AR: Telomerase activity in human development is regulated by human telomerase reverse transcriptase (hTERT) transcription and by alternate splicing of hTERT transcripts. Cancer Res 1998, 58:4168-4172
34. Liu K, Schoonmaker MM, Levine BL, June CH, Hodes RJ, Weng NP: Constitutive and regulated expression of telomerase reverse transcriptase (hTERT) in human lymphocytes. Proc Natl Acad Sci USA 1999, 96:5147-5152